alpha-1 Antitrypsin Monoclonal Antibody (TMF1#4B5), Invitrogen™

Description

MIA1101 targets Alpha1-Antitrypsin in IP applications and shows reactivity with Human samples. The MIA1101 immunogen is purified human a1-Antitrypsin. MIA1101 detects Alpha1-Antitrypsin which has a predicted molecular weight of approximately 46 kDa. MIA1101 was formerly sold as a Seradyn product.

Alpha-1-AT is synthesized in the liver and it acts as an inhibitor of proteases such as trypsin, elastase, chymotrypsin, collagenase, leucocytic proteases, plasmin, and thrombin, which may be released during inflammatory reactions in the lung. In the absence of alpha-1-AT, these enzymes are not inhibited and they may digest pulmonary parenchyma. Alpha-1-AT deficiency is associated with chronic obstructive lung disease (emphysema) and less frequently with hepatic cirrhosis in infants and respiratory distress of the newborn. Increase in alpha-1-AT occurs as an acute phase response to tissue necrosis and inflammation. Serum level of alpha-1-AT is elevated in rheumatoid arthritis, bacterial infections, vasculitis, and carcinomatosis.